The global biosimilars market is expanding rapidly due to the need for cost-effective biologic alternatives, projecting growth to over USD 150 billion by the mid-2030s with a high-teen CAGR. Monoclonal Antibodies (mAbs) are the dominant drug class (44.98% revenue share), while North America leads in current revenue, and the Asia Pacific region is the fastest-growing market. Growth is driven by patent expirations, rising chronic disease prevalence (oncology/autoimmune), and favorable regulatory environments, despite challenges related to patient perception and interchangeability.